TEM Stock Forecast & Price Target

Tempus AI is positioned as a differentiated precision-medicine platform that combines diagnostics, data, and AI, with oncology testing volume up 32% YoY, September xF requisitions up 25% YoY, and data-and-applications revenue up 33% YoY in 3Q26. Its fundamental strength is the growing mix of higher-value, recurring revenue streams: year-to-date data-licensing bookings exceeded $550M, remaining contracted data value was over $1.1 billion at the end of 2025, and management raised FY2026 revenue guidance to $1,600-1,605M while keeping adjusted EBITDA guidance at approximately $65M. The company also has multiple self-funded growth catalysts—MRD expansion, FDA and reimbursement upside for xF and xT CDx, and the pending Personalis acquisition—supported by $854M of cash and a path toward expanding profitability as reinvestment continues.

Tempus AI is exposed to execution and focus risk through its commercial partner relationships, particularly in diagnostics, where coordination issues can weaken operating momentum and dilute management attention. Its revenue visibility also appears uneven because pharma ordering and budgets can shift quarter to quarter as customers reassess priorities, while funding and ordering from the U.S. Department of Veterans Affairs for the Million Veteran Program can fluctuate in both size and frequency. In addition, the pending acquisition of PSNL by TEM introduces binary deal risk: if the transaction fails to close, PSNL may need to increase spending and investment, which can pressure fundamentals further.